Cargando…

Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol

BACKGROUND: Mixed dyslipidemia [elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs), and decreased HDL-C] is common in type 2 diabetes mellitus (T2DM) and is associated with increased cardiovascular risk. Non-HDL-C and apolipoprotein B (ApoB) are the preferred thera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colhoun, Helen M., Leiter, Lawrence A., Müller-Wieland, Dirk, Cariou, Bertrand, Ray, Kausik K., Tinahones, Francisco J., Domenger, Catherine, Letierce, Alexia, Israel, Marc, Samuel, Rita, Del Prato, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007683/ https://www.ncbi.nlm.nih.gov/pubmed/32035487 http://dx.doi.org/10.1186/s12933-020-0991-1

Ejemplares similares

Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab
por: Vallejo-Vaz, Antonio J, et al.
Publicado: (2020)

Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies
por: Ray, Kausik K., et al.
Publicado: (2019)

Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial
por: Ray, Kausik K., et al.
Publicado: (2018)

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk
por: Müller-Wieland, Dirk, et al.
Publicado: (2017)

Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial
por: Leiter, Lawrence A., et al.
Publicado: (2017)

Lower On‐Treatment Low‐Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials
por: Vallejo‐Vaz, Antonio J., et al.
Publicado: (2018)

Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials
por: Leiter, L. A., et al.
Publicado: (2017)

Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials
por: Henry, Robert R., et al.
Publicado: (2018)

Alirocumab Treatment and Achievement of Non‐High‐Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials
por: Bays, Harold E., et al.
Publicado: (2017)

Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials
por: Leiter, L. A., et al.
Publicado: (2018)

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies
por: Colhoun, Helen M., et al.
Publicado: (2016)

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
por: Chapman, M. John, et al.
Publicado: (2011)

Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials
por: Ganda, Om P., et al.
Publicado: (2018)

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
por: Cannon, Christopher P., et al.
Publicado: (2015)

Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
por: Szarek, Michael, et al.
Publicado: (2020)

Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies
por: Ginsberg, Henry N., et al.
Publicado: (2018)

LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials
por: Ginsberg, Henry N., et al.
Publicado: (2021)

Assessment of serum levels of triglycerides, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol in periodontitis patients
por: Penumarthy, Swati, et al.
Publicado: (2013)

Risk assessment of metabolic syndrome in adolescents using the triglyceride/high-density lipoprotein cholesterol ratio and the total cholesterol/high-density lipoprotein cholesterol ratio
por: Chu, Shou-Yu, et al.
Publicado: (2019)

The Association between the Triglyceride to High-density Lipoprotein Cholesterol Ratio and Low-density Lipoprotein Subclasses
por: Moriyama, Kengo
Publicado: (2020)

Triglycerides, total cholesterol, high density lipoprotein cholesterol and low density lipoprotein cholesterol in rats exposed to premium motor spirit fumes
por: Aberare, Ogbevire L., et al.
Publicado: (2011)

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials
por: Colhoun, Helen M, et al.
Publicado: (2014)

Triglyceride to high-density lipoprotein cholesterol ratio and total cholesterol to high-density lipoprotein cholesterol ratio and risk of benign prostatic hyperplasia in Chinese male subjects
por: Zhu, Chen, et al.
Publicado: (2022)

The Relationship between the Triglyceride to High-Density Lipoprotein Cholesterol Ratio and Metabolic Syndrome
por: Shin, Hyun-Gyu, et al.
Publicado: (2017)

The triglyceride-to-high density lipoprotein cholesterol ratio in overweight Korean children and adolescents
por: Yoo, Dong-Yoon, et al.
Publicado: (2017)

Visceral adiposity index and triglyceride/high-density lipoprotein cholesterol ratio in hypogonadism
por: Haymana, Cem, et al.
Publicado: (2017)

Association of adiposity and fitness with triglyceride-to-high-density lipoprotein cholesterol ratio in youth
por: Musa, Danladi Ibrahim, et al.
Publicado: (2023)

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study
por: Langslet, Gisle, et al.
Publicado: (2020)

Triglycerides/Glucose and Triglyceride/High-Density Lipoprotein Cholesterol Indices in Normal and Preeclamptic Pregnancies: A Longitudinal Study
por: Poveda, Natalia Elvira, et al.
Publicado: (2018)

Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo
por: Toth, Peter P., et al.
Publicado: (2016)

Comparison of Methods to Estimate Low-Density Lipoprotein Cholesterol in Patients With High Triglyceride Levels
por: Sajja, Aparna, et al.
Publicado: (2021)

The relationship between triglyceride/high-density lipoprotein cholesterol ratio and coronary microvascular disease
por: Liao, Li ping, et al.
Publicado: (2023)

Association of triglyceride/high-density lipoprotein cholesterol ratio with severe complications of COVID-19
por: Chang, Yoonkyung, et al.
Publicado: (2023)

Cholesterol Remnants, Triglyceride-Rich Lipoproteins and Cardiovascular Risk
por: Baratta, Francesco, et al.
Publicado: (2023)

Triglyceride-Rich Lipoproteins and Remnant Cholesterol in Cardiovascular Disease
por: Heo, Ji Hye, et al.
Publicado: (2023)

Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial
por: Schwartz, Gregory G, et al.
Publicado: (2023)

A 90 minute soccer match decreases triglyceride and low density lipoprotein but not high-density lipoprotein and cholesterol levels
por: Rahnama, Nader, et al.
Publicado: (2009)

Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin
por: Müller-Wieland, Dirk, et al.
Publicado: (2019)

Fasting Serum Triglyceride and High-Density Lipoprotein Cholesterol Levels in Patients Intended to be Treated for Dyslipidemia
por: Kolovou, Genovefa D, et al.
Publicado: (2005)

Predicting insulin resistance using the triglyceride-to-high-density lipoprotein cholesterol ratio in Taiwanese adults
por: Chiang, Jui-Kun, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_b5ifr9tjbddkvtob45p7br64l3